Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA Antigens | 9 | 2021 | 232 | 2.270 |
Why?
|
| Histocompatibility Testing | 16 | 2019 | 154 | 1.790 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2019 | 878 | 1.760 |
Why?
|
| Alleles | 15 | 2021 | 1128 | 1.420 |
Why?
|
| ABO Blood-Group System | 3 | 2019 | 62 | 1.250 |
Why?
|
| Isoantibodies | 3 | 2019 | 114 | 1.240 |
Why?
|
| Unrelated Donors | 6 | 2019 | 50 | 1.190 |
Why?
|
| Graft Rejection | 8 | 2017 | 1065 | 0.980 |
Why?
|
| Amino Acid Substitution | 4 | 2016 | 339 | 0.930 |
Why?
|
| Graft vs Host Disease | 11 | 2019 | 365 | 0.750 |
Why?
|
| Kidney Transplantation | 9 | 2017 | 849 | 0.730 |
Why?
|
| HLA-A24 Antigen | 1 | 2019 | 20 | 0.710 |
Why?
|
| Plasma Exchange | 1 | 2019 | 29 | 0.690 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2013 | 203 | 0.680 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 132 | 0.660 |
Why?
|
| Exons | 5 | 2019 | 450 | 0.630 |
Why?
|
| Pronase | 1 | 2017 | 6 | 0.630 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2017 | 14 | 0.630 |
Why?
|
| Receptors, Fc | 1 | 2017 | 33 | 0.620 |
Why?
|
| Edetic Acid | 1 | 2017 | 43 | 0.590 |
Why?
|
| Immunoassay | 1 | 2017 | 92 | 0.580 |
Why?
|
| Electroencephalography | 1 | 2020 | 709 | 0.570 |
Why?
|
| B-Lymphocytes | 3 | 2017 | 724 | 0.540 |
Why?
|
| Haplotypes | 5 | 2021 | 642 | 0.490 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2019 | 93 | 0.470 |
Why?
|
| Histocompatibility | 5 | 2016 | 71 | 0.460 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2021 | 456 | 0.450 |
Why?
|
| HLA-DRB1 Chains | 3 | 2011 | 28 | 0.450 |
Why?
|
| Autoantibodies | 1 | 2014 | 267 | 0.440 |
Why?
|
| HLA-B Antigens | 8 | 2010 | 35 | 0.400 |
Why?
|
| Decision Trees | 1 | 2011 | 63 | 0.390 |
Why?
|
| Sequence Deletion | 1 | 2011 | 205 | 0.380 |
Why?
|
| Living Donors | 1 | 2014 | 339 | 0.380 |
Why?
|
| Immunogenetics | 2 | 2021 | 9 | 0.370 |
Why?
|
| Base Sequence | 5 | 2019 | 2330 | 0.370 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 373 | 0.360 |
Why?
|
| Liver Transplantation | 2 | 2014 | 1268 | 0.320 |
Why?
|
| Transplantation, Homologous | 10 | 2019 | 996 | 0.310 |
Why?
|
| HLA-C Antigens | 4 | 2015 | 21 | 0.310 |
Why?
|
| Humans | 49 | 2021 | 86645 | 0.300 |
Why?
|
| Complement C4b | 3 | 2014 | 35 | 0.240 |
Why?
|
| Adult | 21 | 2019 | 25648 | 0.230 |
Why?
|
| Hematologic Neoplasms | 4 | 2014 | 329 | 0.230 |
Why?
|
| Cross-Over Studies | 3 | 2020 | 399 | 0.230 |
Why?
|
| Genotype | 3 | 2019 | 1851 | 0.220 |
Why?
|
| Reaction Time | 3 | 2020 | 309 | 0.220 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2012 | 67 | 0.220 |
Why?
|
| Tissue Donors | 6 | 2017 | 463 | 0.220 |
Why?
|
| HLA-A Antigens | 4 | 2010 | 44 | 0.210 |
Why?
|
| Lorazepam | 2 | 2012 | 16 | 0.210 |
Why?
|
| Gene Frequency | 2 | 2021 | 677 | 0.210 |
Why?
|
| Peptide Fragments | 3 | 2014 | 460 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2015 | 763 | 0.210 |
Why?
|
| Young Adult | 12 | 2017 | 5976 | 0.200 |
Why?
|
| Child | 10 | 2019 | 6928 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2017 | 3613 | 0.200 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 1195 | 0.190 |
Why?
|
| Allografts | 2 | 2019 | 172 | 0.190 |
Why?
|
| Infant | 6 | 2017 | 3047 | 0.190 |
Why?
|
| Adolescent | 12 | 2017 | 8982 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 5 | 2017 | 286 | 0.180 |
Why?
|
| Female | 23 | 2019 | 44534 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 346 | 0.180 |
Why?
|
| Nuclear Family | 1 | 2019 | 92 | 0.170 |
Why?
|
| Graft Survival | 3 | 2013 | 884 | 0.170 |
Why?
|
| Fetal Blood | 1 | 2019 | 90 | 0.170 |
Why?
|
| Aged | 10 | 2019 | 18415 | 0.170 |
Why?
|
| Donor Selection | 1 | 2019 | 67 | 0.170 |
Why?
|
| Middle Aged | 19 | 2016 | 25028 | 0.160 |
Why?
|
| Genetics, Population | 1 | 2021 | 394 | 0.160 |
Why?
|
| Male | 23 | 2017 | 40967 | 0.150 |
Why?
|
| Dithiothreitol | 1 | 2017 | 26 | 0.150 |
Why?
|
| Cell Separation | 1 | 2017 | 196 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2017 | 63 | 0.150 |
Why?
|
| Plasmapheresis | 2 | 2014 | 26 | 0.140 |
Why?
|
| Unsupervised Machine Learning | 1 | 2016 | 7 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2010 | 375 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2014 | 66 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 100 | 0.140 |
Why?
|
| Flow Cytometry | 1 | 2017 | 679 | 0.130 |
Why?
|
| Codon | 1 | 2016 | 124 | 0.130 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2015 | 4 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 131 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 238 | 0.130 |
Why?
|
| Antibodies | 1 | 2017 | 350 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2017 | 7993 | 0.130 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2014 | 6 | 0.130 |
Why?
|
| HLA-DP beta-Chains | 1 | 2014 | 8 | 0.130 |
Why?
|
| Pseudogenes | 1 | 2004 | 35 | 0.120 |
Why?
|
| Gorilla gorilla | 1 | 2004 | 41 | 0.120 |
Why?
|
| Transaminases | 1 | 2014 | 34 | 0.120 |
Why?
|
| Spouses | 1 | 2014 | 33 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2017 | 2262 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 89 | 0.120 |
Why?
|
| Birth Order | 1 | 2013 | 8 | 0.110 |
Why?
|
| HLA-DP Antigens | 1 | 2013 | 9 | 0.110 |
Why?
|
| Molecular Sequence Data | 9 | 2012 | 3030 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2011 | 1538 | 0.110 |
Why?
|
| Memory | 2 | 2012 | 225 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 1187 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 853 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 79 | 0.110 |
Why?
|
| Multigene Family | 3 | 2001 | 202 | 0.110 |
Why?
|
| RNA | 1 | 2016 | 560 | 0.110 |
Why?
|
| Hematopoiesis | 1 | 2013 | 163 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2012 | 80 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2012 | 126 | 0.100 |
Why?
|
| GABA Modulators | 1 | 2011 | 9 | 0.100 |
Why?
|
| Vocabulary | 1 | 2011 | 16 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 114 | 0.100 |
Why?
|
| Amino Acids | 1 | 2012 | 252 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 297 | 0.100 |
Why?
|
| HLA-DR Antigens | 2 | 2010 | 61 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 4 | 2001 | 927 | 0.100 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2010 | 21 | 0.100 |
Why?
|
| Random Allocation | 1 | 2011 | 332 | 0.090 |
Why?
|
| Capillaries | 1 | 2010 | 91 | 0.090 |
Why?
|
| Amino Acid Sequence | 6 | 2012 | 2062 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2016 | 730 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 173 | 0.090 |
Why?
|
| Phylogeny | 1 | 2004 | 1137 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 67 | 0.080 |
Why?
|
| Registries | 3 | 2019 | 703 | 0.080 |
Why?
|
| Cognition | 1 | 2012 | 570 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 1 | 1986 | 19 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2379 | 0.070 |
Why?
|
| Transplantation Immunology | 2 | 2021 | 84 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1986 | 213 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 1986 | 177 | 0.070 |
Why?
|
| Genes, MHC Class I | 1 | 1996 | 48 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 1986 | 76 | 0.070 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1985 | 10 | 0.070 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2004 | 3 | 0.060 |
Why?
|
| Risk Factors | 5 | 2014 | 5417 | 0.060 |
Why?
|
| Software | 2 | 2019 | 654 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 1985 | 235 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 1986 | 182 | 0.060 |
Why?
|
| Testis | 1 | 2004 | 152 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2013 | 372 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 839 | 0.060 |
Why?
|
| Recurrence | 2 | 2016 | 1139 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 674 | 0.050 |
Why?
|
| Blood Donors | 2 | 2012 | 26 | 0.050 |
Why?
|
| Siblings | 2 | 2013 | 111 | 0.050 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 44 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1801 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 1985 | 295 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3640 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 193 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 623 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 1577 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1204 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2012 | 502 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2012 | 912 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2004 | 488 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1135 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2004 | 599 | 0.040 |
Why?
|
| Untranslated Regions | 1 | 2019 | 19 | 0.040 |
Why?
|
| Survival Rate | 2 | 2015 | 1863 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 294 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 28 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1805 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 95 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 117 | 0.040 |
Why?
|
| United States | 3 | 2019 | 6674 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 127 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2013 | 1286 | 0.040 |
Why?
|
| Introns | 1 | 2019 | 289 | 0.040 |
Why?
|
| Survivors | 1 | 2019 | 226 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 473 | 0.040 |
Why?
|
| Biopsy | 2 | 2012 | 1163 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1823 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 966 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1753 | 0.040 |
Why?
|
| Age Factors | 2 | 2012 | 1851 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2767 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 285 | 0.040 |
Why?
|
| Mortality | 1 | 2017 | 149 | 0.040 |
Why?
|
| Ileum | 1 | 2016 | 159 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 238 | 0.030 |
Why?
|
| Protein Binding | 2 | 2012 | 1456 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 257 | 0.030 |
Why?
|
| DNA | 1 | 2001 | 1294 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 2705 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 16 | 0.030 |
Why?
|
| Philippines | 1 | 2004 | 23 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2015 | 8491 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 51 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 814 | 0.030 |
Why?
|
| Receptors, KIR | 1 | 2013 | 10 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 943 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 64 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
| Chimerism | 1 | 2013 | 37 | 0.030 |
Why?
|
| Amino Acid Motifs | 2 | 2004 | 116 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2012 | 13 | 0.030 |
Why?
|
| DNA Primers | 2 | 2000 | 543 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 36 | 0.030 |
Why?
|
| Biomarkers | 1 | 1989 | 1718 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2012 | 52 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2012 | 135 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 1982 | 5 | 0.030 |
Why?
|
| Neutrophils | 1 | 2013 | 307 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 334 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 826 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2012 | 309 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 6509 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 158 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 797 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 999 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 229 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 485 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 384 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1098 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 2010 | 52 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 39 | 0.020 |
Why?
|
| Illinois | 1 | 2011 | 462 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 859 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 364 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 722 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 881 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 492 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 78 | 0.020 |
Why?
|
| Rituximab | 1 | 2009 | 116 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 639 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1988 | 39 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 678 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1990 | 315 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 170 | 0.020 |
Why?
|
| Albuminuria | 1 | 1988 | 153 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2009 | 238 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 29 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1019 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1996 | 92 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 1379 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1996 | 122 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 1986 | 123 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1830 | 0.020 |
Why?
|
| Spermatocytes | 1 | 2004 | 8 | 0.020 |
Why?
|
| Creatinine | 1 | 1986 | 338 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1986 | 337 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 509 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2004 | 258 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 351 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1376 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1993 | 393 | 0.010 |
Why?
|
| Histones | 1 | 2004 | 311 | 0.010 |
Why?
|
| Time Factors | 1 | 2010 | 5210 | 0.010 |
Why?
|
| HLA-B15 Antigen | 1 | 2001 | 3 | 0.010 |
Why?
|
| Genome | 1 | 2004 | 372 | 0.010 |
Why?
|
| Gene Conversion | 1 | 2001 | 25 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2001 | 106 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2001 | 48 | 0.010 |
Why?
|
| Animals | 2 | 2004 | 26582 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 245 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1989 | 82 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1989 | 177 | 0.010 |
Why?
|
| Kidney | 1 | 1985 | 1241 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 1981 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1458 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2000 | 535 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 1991 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1990 | 74 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1990 | 59 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1990 | 71 | 0.010 |
Why?
|
| Length of Stay | 1 | 1982 | 703 | 0.010 |
Why?
|
| Exercise Test | 1 | 1988 | 164 | 0.000 |
Why?
|
| Hospitalization | 1 | 1982 | 849 | 0.000 |
Why?
|
| Nephrectomy | 1 | 1988 | 294 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1988 | 1143 | 0.000 |
Why?
|